Skip to main content
HALO logo

Halozyme Therapeutics, Inc. (HALO) Stock: Price, Forecast & Analyst Target

Halozyme Therapeutics, Inc. (HALO) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $91.35 (-1.82%), as of the Nov 20, 2026 trading session; market cap $10.4B. Expected results Feb 16, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 9.68× (cash as of Sep 30, 2026) · expected results Feb 16, 2027

$91.35 −$1.69 (-1.82%) Market Cap $10.4B

Halozyme Therapeutics, Inc. · HALO · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Halozyme is a drug-delivery platform licensor rather than a conventional developer dependent mainly on medicines it commercializes itself: ENHANZE enables under-the-skin administration of partner therapies, while the company earns royalties, product revenue, bulk-enzyme sales, milestones and collaboration revenue. Durable royalty expansion must carry the story, because leverage is substantial and the economics remain tied to partner medicines using the platform.

Price as of Nov 20, 2026

Key Statistics

95 of 100

MoonshotScore v2 · Halozyme Therapeutics (HALO)

Exceptional
Business Quality Elite (96)
Financial Safety Sound (78)
Valuation Fair (63)
Growth Durability Compounding (96)
Momentum Surging (83)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.

  • quarterly revenue $354M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 3.48 · Piotroski F 7

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HALO (58 recorded, newest six shown)
RecordedScoreBand
96Exceptional
96Exceptional
96Exceptional
95Exceptional
95Exceptional
95Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$91.35
Change on the day-1.82%
52-week range$61.23–$134.00
Market capitalisation$10.4B—
Price / earnings (trailing)22.85
Shares traded on the day1.43M
Beta (volatility vs the S&P 500)0.9

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $62, high $131, latest $91. 4 reported quarters marked, 3 above and 1 below the recorded estimate. 1 other dated event marked. $131 $62 high $131 Feb 17, 2026 · Earnings results · reported below the recorded estimate · close $711May 11, 2026 · Earnings results · reported above the recorded estimate · close $642Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $1033Nov 5, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $1044Nov 5, 2026 · Earnings results · reported above the recorded estimate · close $1045 Oct 17, 2025 Nov 20, 2026 · $91 $67Oct 17, 2025$65Oct 31, 2025$70Nov 14, 2025$71Nov 28, 2025$62Dec 12, 2025$69Dec 26, 2025$72Jan 9, 2026$69Jan 23, 2026$81Feb 6, 2026$71Feb 20, 2026$67Mar 6, 2026$63Mar 20, 2026$64Apr 2, 2026$69Apr 17, 2026$64May 1, 2026$67May 15, 2026$67May 29, 2026$70Jun 12, 2026$75Jun 26, 2026$76Jul 10, 2026$82Jul 24, 2026$103Aug 7, 2026$108Aug 21, 2026$110Sep 4, 2026$112Sep 18, 2026$110Oct 2, 2026$122Oct 16, 2026$131Oct 30, 2026$100Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • So we do plan to give 2027 guidance and an update on our long-range outlook when we report fourth quarter results in February.

    Darren Snellgrove · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Halozyme Therapeutics (HALO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Moderate
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation

Financial Health Strong
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Halozyme Therapeutics (HALO), and what does it report?

Short answer · as of

The biotechnology label suggests a business funded chiefly by its own therapeutic pipeline.

Halozyme instead monetizes a patented recombinant human hyaluronidase enzyme across medicines developed and sold by major pharmaceutical partners, alongside Hylenex product sales. Reported revenue therefore combines royalties, products, bulk enzyme, sales-based milestones and collaborative agreements, with royalties forming the largest category.

2 · Latest results

What do the latest results show for Halozyme Therapeutics (HALO)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $354M.

The latest reported period produced the strongest revenue, gross profit, operating profit, net income and operating cash flow in the presented quarterly series. Reported revenue and earnings also surpassed expectations after the preceding period had done the same, extending the recovery from the earlier loss and earnings miss.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$492.97M Sep 30, 2026
Latest quarter · R&D
$27.78M Sep 30, 2026
Latest quarter · SG&A
$58.24M Sep 30, 2026
Latest quarter · FMP standardized operating result
$294.97M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$492.97M$27.78M$58.24M$294.97M
Jun 30, 2026$481.00M$27.66M$57.00M$287.65M
Mar 31, 2026$376.71M$25.56M$57.88M$184.52M
Dec 31, 2025$451.77M$31.90M$77.03M$240.70M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$492.97M Nov 5, 2026
Latest report · revenue estimate
$491.63M Nov 5, 2026
Latest report · revenue vs estimate
Above estimate Nov 5, 2026
Latest report · EPS vs estimate
Above estimate Nov 5, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 5, 2026$492.97M$491.63M$2.3900$2.3000
Aug 6, 2026$481.00M$402.28M$2.2800$1.7900
May 11, 2026$376.71M$358.60M$1.6000$1.5500
Feb 17, 2026$451.77M$435.71M−$0.2400$2.1500
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$354M$175M$1.43 (diluted)
Q4 FY2025$452M-$142M-$1.20 (diluted)
Q1 FY2026$377M$150M$1.22 (diluted)
Q2 FY2026$481M$230M$1.90 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Halozyme Therapeutics (HALO)?

Short answer

Cash and short-term investments were $1.07B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $258.27M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Halozyme pairs high gross and operating margins with recurring positive operating cash flow and modest capital spending, giving the platform strong cash-generation characteristics. Liquidity ratios remain comfortable and the quality screens do not signal immediate distress.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$258.27M Sep 30, 2026
Previous quarter · operating cash flow
$240.89M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$258.27M−$3.05M
Jun 30, 2026$240.89M−$4.17M
Mar 31, 2026$180.08M−$3.74M
Dec 31, 2025$219.03M−$1.43M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Halozyme Therapeutics (HALO)?

Short answer · as of

The next earnings report is expected on Feb 16, 2027.

Royalty revenue is the most informative near-term operating test. Management expects it to keep rising sequentially, but has cautioned that the increase may be less pronounced than the recent step-up. Revenue and earnings against current expectations will show whether that moderation is consistent with continued operating momentum.

What management is planning

Management's statement is quoted under Upcoming events

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Oct 3, 2025 — 13 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Halozyme Therapeutics compare with its peers?

Short answer

Halozyme Therapeutics's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a conventional biotech that must fund and commercialize its own therapies, Halozyme can participate in partner-product sales through ENHANZE royalties. Compared with a typical drug-delivery supplier, its revenue mix reaches beyond product and bulk-enzyme sales into royalties, milestones and collaborations. That structure supports high margins and low capital intensity, but leaves commercial execution largely with pharmaceutical partners while Halozyme retains the economic exposure.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Exelixis, Inc. (EXEL) Same industry, near in market value$64.63 Nov 20, 2026$15.8B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Halozyme Therapeutics (HALO) — this page$91.35$10.4B95
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$156.59 Nov 19, 2026$15.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.67 Nov 20, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$64.98 Nov 19, 2026$7.11B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$124.02 Nov 19, 2026$8.09B88 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Named competitor$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Named competitor$84.80 Nov 19, 2026$9.37B73 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$90.00 – $130.00
Consensus target
$110.67
Median target
$109.50

Consensus record · Captured .

Measured against a quoted price of $91.35 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026

Transactions
57
Identified insiders
4
Purchases
0
Sales
37
Other transactions
20

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
798 Period end Sep 30, 2026
Previous quarter · holders
693 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.13,668,566
Vanguard Capital Management LLC5,106,451
State Street Corp5,063,578
Vanguard Portfolio Management LLC4,986,956
Jane Street Group, LLC3,605,900

Tracked investors

Which of the 16 named investors we follow held HALO in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.16%$36.24MTrimmed −29.1% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Halozyme Therapeutics (HALO)?

Read these with our analysis →

Common Questions About HALO (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

How does ENHANZE make money for Halozyme?

Halozyme licenses the delivery platform to pharmaceutical partners and earns through royalties, bulk-enzyme supply, milestones and collaborative agreements as partner programs advance and sell. Royalties are currently the largest reported revenue category.

Why can Halozyme grow without selling every medicine itself?

Partners develop and commercialize medicines that use ENHANZE, allowing Halozyme to participate economically without owning each underlying therapy. Demand therefore depends on partner launches, adoption and commercial performance.

What is Hypercon meant to add to Halozyme?

Management presents Hypercon as a future source of product launches and royalty revenue. Its projected contribution sits well beyond the current reporting horizon, so ENHANZE-linked performance remains the more immediate operating evidence.

Are ENHANZE royalties more important than Hylenex sales?

Royalties are the largest reported revenue category, while all product revenue is reported as a smaller category. Hylenex is Halozyme’s leading proprietary product, but the segment disclosure does not isolate its contribution within product sales.

What is the HALO stock price today?

The last price recorded for Halozyme Therapeutics, Inc. (HALO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the HALO price target?

The analyst consensus price target for Halozyme Therapeutics, Inc. (HALO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 78 figures on this page — 2 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Cash, investments and debt; Management outlook — dated call excerpts
  • 1. What is Halozyme Therapeutics (HALO), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Halozyme Therapeutics (HALO)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Halozyme Therapeutics (HALO)?: Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Distress and quality screens; Quarterly income statement (USD thousands)
  • 4. What should you watch next at Halozyme Therapeutics (HALO)?: Management outlook — dated call excerpts; Next earnings report; Reported versus estimated, last 8 quarters; Revenue by segment
  • 5. How does Halozyme Therapeutics compare with its peers?: Business description; Revenue by segment; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions)
  • FAQ: How does ENHANZE make money for Halozyme?: Business description; Revenue by segment
  • FAQ: Why can Halozyme grow without selling every medicine itself?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: What is Hypercon meant to add to Halozyme?: Management outlook — dated call excerpts; Named officers; Revenue by segment
  • FAQ: Are ENHANZE royalties more important than Hylenex sales?: Revenue by segment; Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold HALO

Funds in our ETF coverage that list HALO among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
FFLS ETF3.26%